Lorient Closes $500 Million Fund III to Scale Founder-Led Healthcare Companies

Miami, FL – July 10, 2025 – Lorient Capital, an investment firm focused exclusively on healthcare, today announced the final close of Lorient Healthcare Fund III, with $500 million in total commitments. The fund, which closed on June 30^th, was oversubscribed, surpassing its original $350 million target.

Lorient partners with founder-led healthcare companies in the middle market, bringing sector expertise, hands-on operational capabilities, and a repeatable approach to scaling mission-driven businesses. The firm has built a track record of supporting improvements in clinical outcomes, workforce efficiency, and access to care across the U.S. healthcare system.

“Fund III represents a major step forward in our mission to support companies working to improve the healthcare system and create long-term, sustainable value,” said David Berman and Jordan Broome, Co-Managing Partners at Lorient Capital. “We’re deeply grateful to our existing partners for their continued support and to our new investors who share our conviction that healthcare investing can drive both strong returns and meaningful impact.”

A Disciplined Strategy in Healthcare

Lorient targets control-oriented investments in healthcare providers, services, and technology companies. The firm focuses on sectors experiencing transformation and growth, such as consumer-directed healthcare, post-acute care, behavioral health, provider enablement, and tech-enabled services, where its operational model can help drive performance.

Lorient-backed companies aim to advance quality of care, expand access in underserved and rural markets, address workforce shortages, integrate care for vulnerable populations, and support the transition to value-based models. One of Lorient’s five core operational domains is quality, which is actively managed and measured in partnership with clinical leaders using the firm’s proprietary tools and operating approach.

Since inception, Lorient has completed 20 platform investments and over 75 add-on acquisitions. The firm’s nine realized exits reflect a consistent ability to build, scale, and create value across its portfolio.

Morpheus: Lorient’s Operational Advantage

At the center of Lorient’s model is Morpheus, the firm’s proprietary technology platform. Morpheus consolidates fragmented clinical, operational, and financial data into real-time, actionable insights that support growth and performance.

“Morpheus is our engine for accelerating transformation,” said Jordan Broome. “It enables us to go beyond capital, embedding the tools, insights, and capabilities our portfolio companies need to scale effectively and deliver better care.”

More than a reporting system, Morpheus integrates directly into a company’s workflows and infrastructure, benchmarking performance, identifying operational gaps, and supporting leadership teams. This drives faster decision-making, higher-quality care, and closer alignment between day-to-day operations and long-term strategy.

Looking Ahead

With Fund III, Lorient will continue to support high-quality management teams in scaling healthcare businesses that blend operational rigor with clinical focus. The close of Fund III reinforces Lorient’s position as a strategic partner to founders and investors and provides added momentum to execute on its disciplined, operations-led investment strategy.